Clostridioides difficile infection in US hospitals: a national inpatient sample study.

Clostridioides difficile Community acquired clostridioides difficile infection (CCDI) Health care cost and utilization project (HCUP) Hospital-aquired clostridioides difficile infection (HCDI) National inpatient sample (NIS)

Journal

International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899

Informations de publication

Date de publication:
Oct 2020
Historique:
accepted: 20 05 2020
pubmed: 20 6 2020
medline: 24 6 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

Hypervirulent strains of Clostridioides difficile have altered the landscape of hospital and community outbreaks. We aim to examine and compare spatiotemporal trends, incidence, hospital teaching status, mortality, and cost associated with hospital-acquired Clostridioides difficile infection (HCDI) and community-acquired Clostridioides difficile infection (CCDI). Retrospective cohorts were studied using data from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) from 2006 to 2015. A total of 76,124 cases of HCDI and 190,641 cases of CCDI were identified within the study period. The incidence of HCDI decreased from 8555 in 2006 to 7191 in 2015. Mortality also decreased during the same period (5.9% in 2006 to 1.4% 2015, p < 0.0001). Conversely, CCDI cases increased from 13,823 in 2006 to 20,637 in 2015. CCDI mortality decreased during the same period (4.3% in 2006 to 1.9% 2015, p < 0.0001). Rural hospital centers experienced the sharpest decline in HCDI mortality compared to urban and urban teaching centers (3.8%, p < 0.0001 vs 2.8%, p < 0.0001 vs 2.1%, p < 0.0001). Multivariate logistic regression indicated that increasing age (p = 0.0001), increasing hospital length of stay (p = 0.0001), and Medicare insurance (p = 0.002) were significant predictors of mortality for CDI mortality. Geospatial mapping of CCDI and HCDI revealed that the Eastern and Southern US experienced the largest incidence of CDI over 10 years. The incidence of HCDI has decreased in the past decade while the incidence of CCDI hospitalization is sharply on the rise. While hospital length of stay and mortality has decreased over time, the cost of treating CDI remains high.

Sections du résumé

BACKGROUND BACKGROUND
Hypervirulent strains of Clostridioides difficile have altered the landscape of hospital and community outbreaks. We aim to examine and compare spatiotemporal trends, incidence, hospital teaching status, mortality, and cost associated with hospital-acquired Clostridioides difficile infection (HCDI) and community-acquired Clostridioides difficile infection (CCDI).
METHODS METHODS
Retrospective cohorts were studied using data from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) from 2006 to 2015.
RESULTS RESULTS
A total of 76,124 cases of HCDI and 190,641 cases of CCDI were identified within the study period. The incidence of HCDI decreased from 8555 in 2006 to 7191 in 2015. Mortality also decreased during the same period (5.9% in 2006 to 1.4% 2015, p < 0.0001). Conversely, CCDI cases increased from 13,823 in 2006 to 20,637 in 2015. CCDI mortality decreased during the same period (4.3% in 2006 to 1.9% 2015, p < 0.0001). Rural hospital centers experienced the sharpest decline in HCDI mortality compared to urban and urban teaching centers (3.8%, p < 0.0001 vs 2.8%, p < 0.0001 vs 2.1%, p < 0.0001). Multivariate logistic regression indicated that increasing age (p = 0.0001), increasing hospital length of stay (p = 0.0001), and Medicare insurance (p = 0.002) were significant predictors of mortality for CDI mortality. Geospatial mapping of CCDI and HCDI revealed that the Eastern and Southern US experienced the largest incidence of CDI over 10 years.
CONCLUSION CONCLUSIONS
The incidence of HCDI has decreased in the past decade while the incidence of CCDI hospitalization is sharply on the rise. While hospital length of stay and mortality has decreased over time, the cost of treating CDI remains high.

Identifiants

pubmed: 32556651
doi: 10.1007/s00384-020-03646-3
pii: 10.1007/s00384-020-03646-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1929-1935

Références

Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN (2007) Increasing prevalence and severity of clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142(7):624–631
pubmed: 17638799
Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH (2016) Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis 16(1):447. https://doi.org/10.1186/s12879-016-1786-6
pubmed: 27562241 pmcid: 5000548
Huang H, Weintraub A, Fang H, Nord CE (2009) Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 34(6):516–522
pubmed: 19828299
Gupta A, Khanna S (2014) Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 7:63–72
pubmed: 24669194 pmcid: 3962320
Johnson S (2009) Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 58(6):403–410. https://doi.org/10.1016/j.jinf.2009.03.010
pubmed: 19394704
Zimlichman E, Henderson D, Tamir O et al (2013) Health care–associated infections: a meta-analysis of costs and financial impact on the US health care system. J Am Med Assoc Intern Med 173(22):2039–2046
Centers for Disease Control and Prevention (2012) Annual report for the emerging infections program for Clostridium difficile infection. https://www.cdc.gov/hai/eip/pdf/cdiff/2012-annual-report . Accessed August 2019
Centers for Disease Control and Prevention (2016) Annual report for the emerging infections program for Clostridium difficile infection. http://wwwcdcgov/hai/eip/Annual-CDI-Report-2016html Updated January 2019. Accessed August 2019
Wenzler E, Mulugeta SG, Danziger LH (2015) The antimicrobial stewardship approach to combating clostridium Difficile. Antibiotics. 4(2):198–215
pubmed: 27025621 pmcid: 4790327
Carling P, Fung T, Killion A, Terrin, Barza M (2003) Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 24(9):699–706
pubmed: 14510254
McDonald CL, Gerding DN, Johnson S et al (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66(7):e1–e48
pubmed: 6018983 pmcid: 6018983
Eze P, Balsells E, Kyaw MH, Nair H (2017) Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis. J Glob Health 7(1). https://doi.org/10.7189/jogh.07.010417
Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN (2017) Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology 153(2):430–438
pubmed: 28479377
Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DDK, Hernandez AV, Donskey CJ, Fraser TG (2015) Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 36(4):452–460
pubmed: 25626326
Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J, McDonald LC (2010) Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 16(2):197–204
pubmed: 20113547
Anderson DJ, Rojas LF, Watson S et al (2017) Identification of novel risk factors for community-acquired Clostridium difficile infection using spatial statistics and geographic information system analyses. PloS One 12(5)
Longtin Y, Paquet-Bolduc B, Gilca R, Garenc C, Fortin E, Longtin J, Trottier S, Gervais P, Roussy JF, Lévesque S, Ben-David D, Cloutier I, Loo VG (2016) Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C difficile infections: a quasi-experimental controlled study. JAMA Intern Med 176(6):796–804
pubmed: 27111806 pmcid: 27111806
Dubberke ER, Olsen MA, Stwalley D et al (2016) Identification of Medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis. PLOS ONE 11(2)
Medicare payment advisory commission. A data book : healthcare spending and the Medicare program. http://www.medpac.gov . updated June 2019. Accessed September, 2019
Weiss AJ, Elixhauser A. Overview of hospital stays in the United States, HCUP statistical brief#180. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb180-Hospitalizations-United-States-2012.pdf . Updated September 2014. Accessed September 2019
Ayanian JZ, Weissman JS (2002) Teaching hospitals and quality of care: a review of the literature. Milbank Q 80(3):569–593
pubmed: 12233250 pmcid: 2690120
Pollack LA, Van Santen KL, Weiner LM, Dudeck MA, Edwards JR, Srivinasan A (2016) Antibiotic stewardship programs in U.S. acute care hospitals: findings from the 2014 national healthcare safety network annual hospital survey. Clin Infect Dis 63(4):443–449
pubmed: 27199462 pmcid: 6537894
Tickler IA, Goering RV, Whitmore JD, Lynn AN, Persing DH, Tenover FC (2014) Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother 58(7):4214–4218
pubmed: 24752264 pmcid: 4068552
Waslawski S, Lo ES, Ewing SA, Young VB, Aronoff DM, Sharp SE, Novak-Weekley SM, Crist AE, Dunne WM, Hoppe-Bauer J, Johnson M, Brecher SM, Newton DW, Walk ST (2013) Clostridium difficile ribotype diversity at six health care institutions in the United States. J Clin Microbiol 51(6):1938–1941
pubmed: 23554188 pmcid: 3716112
Thornton CS, Rubin JE, Greninger AL, Peirano G, Chiu CY, Pillai DR (2018) Epidemiological and genomic characterization of community-acquired Clostridium difficile infections. BMC Infect Dis 18(1):1–9

Auteurs

Daryl Ramai (D)

Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, 11201, USA. dramai@tbh.org.

Khoi Paul Dang-Ho (KP)

Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, 11201, USA.

Chris Lewis (C)

Windward Islands Research and Education Foundation, St George's University School of Medicine, Saint George, Grenada.

Paul J Fields (PJ)

Windward Islands Research and Education Foundation, St George's University School of Medicine, Saint George, Grenada.

Andrew Ofosu (A)

Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Brooklyn, NY, USA.

Mohamed Barakat (M)

Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Brooklyn, NY, USA.

Ali Aamar (A)

Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Brooklyn, NY, USA.

Emmanuel Ofori (E)

Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Brooklyn, NY, USA.

Jonathan Lai (J)

Department of Pathology, McGill University, Montreal, QC, Canada.

Gandhi Lanke (G)

Department of Internal Medicine, Covenant Medical Center, Lubbock, TX, USA.

Amaninder Dhaliwal (A)

Division of Gastroenterology, University of Nebraska Medical Center, Omaha, NE, USA.

Madhavi Reddy (M)

Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Brooklyn, NY, USA.

James Gasperino (J)

Division of Critical Care Medicine, The Brooklyn Hospital Center, Brooklyn, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH